title: [The bone mineral density and the markers of the osseous circle in children with non-toxic parenchymatous or nodular goiter long-time treated with L-thyroxine].
abstract: The aim of the study was the appreciation of the influence of a therapy with L-thyroxine on the metabolism and density of the osseous tissue (BMD) in children with an euthyroid diffuse and nodular goiter. The examinations included 50 children (5 boys and 45 girls). Mean age of the investigated group: 17 years, time of therapy 2-5 years. The daily dose of L-thyroxine was not higher than 1-2 microg/kg body mass. All the children were in clinical and hormonal euthyrosis. The control group consisted of 50 healthy children (12 boys and 38 girls), mean age 16,16 years. A correlation between the age of the children, TSH level and the markers of the osseous circle was not observed. The mean level of TSH was statistical significant lower in the examined group. In the examined group the level of PTH and ICTP in the blood serum was (PTH: 35.83+/-8.34 pg/m vs 37.21+/-7.17 pg/ml); ICTP (8.7+/-3.87 microg/l vs 15.11+/-5.7 microg/l) was lower in the control group but the difference was statistical not significant (p=0.07). The mean concentration of PICP in the investigated group was significant lower in comparison with the control group. The mean level ICTP between the examined and control group was statistical significant (p<0.05). The mean concentration of osteocalcine (OC) in the treated with L-thyroxine was statistical not significant.
authors.affiliation: Katedra i Klinika Endokrynologii Wieku Rozwojowego AM we Wrocławiu, Wrocław. teresa.zak@post.pl
authors.forename: Teresa
authors.initials: T
authors.lastname: Zak
authors.forename: Anna
authors.initials: A
authors.lastname: Golenko
authors.forename: Renata
authors.initials: R
authors.lastname: B Wasikowa
authors.forename: Diana
authors.initials: D
authors.lastname: Jedrzejuk
authors.forename: Anna
authors.initials: A
authors.lastname: Noczyńska
mesh_terms: D000293:Adolescent; D015519:Bone Density / Q000187:drug effects*; D001842:Bone and Bones / Q000378:metabolism*; D016022:Case-Control Studies; D024042:Collagen Type I; D005260:Female; D006044:Goiter, Nodular / Q000097:blood / Q000188:drug therapy* / Q000378:metabolism*; D006801:Humans; D008297:Male; D015675:Osteocalcin / Q000187:drug effects; D010281:Parathyroid Hormone / Q000097:blood; D010446:Peptide Fragments / Q000097:blood; D010455:Peptides; D011347:Procollagen / Q000097:blood; D013972:Thyrotropin / Q000097:blood*; D013974:Thyroxine / Q000494:pharmacology*; D016896:Treatment Outcome
chemical_list: D024042:Collagen Type I; D010281:Parathyroid Hormone; D010446:Peptide Fragments; D010455:Peptides; D011347:Procollagen; C052929:collagen type I trimeric cross-linked peptide; D015675:Osteocalcin; D013972:Thyrotropin; D013974:Thyroxine